Infasurf

Drug Overview

In the specialized field of PULMONOLOGY, managing neonatal respiratory health is one of the most critical interventions. INFASURF is a life-saving therapeutic agent utilized in neonatal intensive care to stabilize the lungs of premature infants. It belongs to the DRUG CLASS known as PULMONARY SURFACTANTS. These substances are essential for human life as they maintain the structural integrity of the air sacs.

When an infant is born prematurely, their body often lacks enough natural surfactant. This leads to RESPIRATORY DISTRESS SYNDROME (RDS), where the lungs collapse with every breath. INFASURF acts as a TARGETED THERAPY to replace this missing biological component, allowing for immediate stabilization of gas exchange and preventing the progression of chronic respiratory failure.

• Generic Name: Calfactant
• US Brand Names: INFASURF
• Drug Class: PULMONARY SURFACTANT (Natural Bovine Derived)
• Route of Administration: Intratracheal Suspension
• FDA Approval Status: FDA approved for the prevention and treatment of RDS in premature infants.

What Is It and How Does It Work? (Mechanism of Action)

The efficacy of INFASURF is rooted in its ability to physically alter the environment within the alveoli. Its mechanism is based on the management of surface tension at the molecular level.

The inner surface of the alveoli is lined with fluid. The attractive forces between water molecules create surface tension that pulls the air sacs closed. In a healthy lung, natural surfactant intercalates between these molecules to break that tension. INFASURF, derived from bovine lung extract, contains high concentrations of phospholipids and specific surfactant proteins (SP B and SP C).

When administered through an endotracheal tube, it spreads across the internal surface of the lungs. At the molecular level, the phospholipids form a monolayer at the air liquid interface. This reduces surface tension to near zero levels during exhalation. Physiologically, this prevents total alveolar collapse, maintaining a Functional Residual Capacity (FRC). The drug significantly reduces the pressure needed for the next breath, improving lung compliance and reducing the “work of breathing.”

FDA Approved Clinical Indications

Primary Indication

The primary PULMONOLOGY indication for INFASURF is the prevention and treatment of RESPIRATORY DISTRESS SYNDROME (RDS) in premature infants.

• Prophylaxis: Administered to high risk infants (usually under 29 weeks gestation) within thirty minutes of birth.
• Rescue: Administered to infants showing clinical signs of RDS who require mechanical ventilation.

Other Approved and Off-Label Uses

• Meconium Aspiration Syndrome (Off-Label): Used to wash out or replace inactivated surfactant.
• Neonatal Pneumonia (Off-Label): Supporting lung function when infection damages the natural surfactant layer.

Primary Pulmonology Indications:

• Improving Ventilation: Ensuring a larger surface area is available for gas exchange by preventing collapse.
• Reducing Exacerbations: Preventing acute respiratory failure and the need for high pressure ventilation.
• Slowing Function Decline: Reducing the risk of Bronchopulmonary Dysplasia (BPD).

Dosage and Administration Protocols

INFASURF must be administered by a qualified professional in a hospital setting with advanced respiratory monitoring.

Indication	Standard Dose	Frequency
RDS Prophylaxis/Treatment	3 mL per kg of birth weight	Every 6 to 12 hours (up to 4 doses)

Administration Instructions

The suspension must be at room temperature and gently swirled (not shaken). The dose is delivered in small bursts (aliquots) through a catheter into the endotracheal tube. The infant is often positioned to allow gravity to distribute the fluid.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Current research results (2020 to 2026) demonstrate that calfactant significantly reduces neonatal mortality. Success is measured by improved oxygenation and reduced air leaks.

Numerical data from clinical trials show that infants treated with INFASURF experienced a rapid increase in the PaO2/FiO2 ratio. Compared to synthetic surfactants, natural calfactants reduce the risk of pneumothorax by 30% to 50%. Research result data also indicate that infants receiving surfactant therapy spend fewer days on mechanical ventilation. This reduction in “ventilator days” is a key respiratory metric for preventing the decline of lung function. Numerical data supports a reduction in the overall mortality of infants with severe RDS by nearly 40% since the implementation of standardized surfactant protocols.

Safety Profile and Side Effects

BLACK BOX WARNING: There is currently NO BLACK BOX WARNING for INFASURF. It must only be administered by clinicians trained in neonatal intubation.

Common Side Effects (greater than 10%)

• Transient Bradycardia: A temporary slowing of the heart rate during dosing.
• Oxygen Desaturation: A brief drop in blood oxygen levels during administration.

Serious Adverse Events

• Endotracheal Tube Obstruction: The thick suspension may block the breathing tube.
• Pulmonary Hemorrhage: Rare but severe bleeding into the lungs.
• Reflux: The medication may back up into the tube during delivery.

Management Strategies

• Monitoring: Continuous EKG and pulse oximetry are mandatory.
• Suctioning: Avoid suctioning for at least one hour after dosing to allow the drug to settle.

Research Areas

Direct Clinical Connections

Active research (2024 to 2026) is investigating the drug’s impact on airway remodeling and pulmonary vascular resistance. Early stabilization of the alveoli may prevent the inflammatory cascade that leads to permanent scarring.

Generalization

Research is focused on NOVEL DELIVERY SYSTEMS, such as Less Invasive Surfactant Administration (LISA), where the drug is given via a thin catheter while the infant breathes on their own. This avoids full intubation. Clinical trials are also exploring “Smart” monitors that use digital tracking to predict which infants will need additional doses.

Severe Disease and Precision Medicine

Researchers are using BIOLOGIC phenotyping to identify infants with specific protein deficiencies. This moves toward a TARGETED THERAPY approach to prevent end stage lung disease.

Disclaimer: This information should be interpreted as emerging but not definitive evidence. Statements implying proven Treg expansion, reliable autoantibody suppression via calfactant, or the established effectiveness of novel delivery systems like LISA in all neonatal populations should be treated as investigational unless supported by direct clinical evidence. Infasurf is an approved pulmonary surfactant for RDS, but its role in specific biologic phenotyping and its long-term impact on preventing airway remodeling remain under active clinical study.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Chest X-ray to confirm the “ground glass” appearance of RDS.
• Vitals: Continuous heart rate and blood pressure monitoring.
• Screening: Review of prenatal steroid use.

Monitoring and Precautions

• Vigilance: The team must adjust ventilator settings immediately as lung compliance improves.
• Follow up: Long term monitoring of lung function to screen for obstructive airway diseases.

Do’s and Don’ts

• DO ensure the endotracheal tube is correctly positioned before dosing.
• DO monitor for sudden improvements in lung function to avoid over ventilation.
• DON’T shake the vial; swirling is required.
• DON’T suction the airway immediately after administration.
• DON’T delay treatment if the infant meets RDS criteria.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. INFASURF is a high alert medication that must only be administered by licensed professionals. Always seek the advice of a qualified health provider for neonatal care questions. Never disregard professional medical advice because of something read here. Use must be supervised by a specialist in PULMONOLOGY or Neonatology.